Oncogene News and Research

RSS

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials.

8 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

Internal production of hydrogen peroxide can lead cells to exit cell cycle and become senescent

What happens inside cells when they detect the activation of a cancer-inducing gene? Sometimes, cells are able to signal internally to stop the cell cycle. Such cells are able to enter, at least for a time, a protective non-growth state.

30 Aug 2014

Scientists discover predictive marker to classify breast cancer patients for effective treatment

Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.

21 Aug 2014

Research offers promise for personalized RNA combination therapies to treat lung cancer

Small RNA molecules, including microRNAs (miRNAs) and small interfering RNAs (siRNAs), offer tremendous potential for new therapeutic agents to inhibit cancer cell growth. However, delivering these small RNAs to solid tumors remains a significant challenge, as the RNAs must target the correct cells and avoid being broken down by enzymes in the body.

15 Aug 2014

Researchers gain rare insight into pregnancy-associated breast cancer

During pregnancy, certain hormones trigger specialized mammary stem cells to create milk-producing cells essential to lactation.

13 Aug 2014

MIT researchers generate liver tumors in adult mice

Sequencing the genomes of tumor cells has revealed thousands of mutations associated with cancer. One way to discover the role of these mutations is to breed a strain of mice that carry the genetic flaw — but breeding such mice is an expensive, time-consuming process.

7 Aug 2014

Researchers find molecule that irreversibly interferes with activity of mutated cancer gene

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

29 Jul 2014

Cancer researchers find molecule that irreversibly interferes with KRAS gene

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

29 Jul 2014

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report.

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

TCGA finds novel mutations in key cancer-causing pathway in lung adenocarcinoma

Researchers from The Cancer Genome Atlas Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer.

10 Jul 2014

Discovery points the way to potential new strategies to treat blood disorders

Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, an Indiana University-led research team has reported.

4 Jul 2014

Cyclin D protein activates key tumor suppressor

Researchers at the University of California, San Diego School of Medicine say a protein essential to regulating cell cycle progression - the process of cell division and replication - activates a key tumor suppressor, rather than inactivating it as previously thought.

3 Jul 2014

UCSB researchers explore genetic underpinnings of nerve-cell spacing

The functional organization of the central nervous system depends upon a precise architecture and connectivity of distinct types of neurons.

27 Jun 2014

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD.

23 Jun 2014

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.

20 Jun 2014

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels.

19 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014